Figure 5.
The RSPO3-induced hematopoietic phenotype requires Wnt ligands. (A) Schematic depicting the LGK974 dosing regimen. (B) Image of representative pieces of small intestine from control and RSPO3 animals of each treatment group; n = 3 to 10 per group. (C) Representative FACS plots and corresponding bar graph quantifying erythroid progenitors in control and RSPO3 animals of each treatment group; n = 3 to 10 per group. (D) Absolute number of RBCs in peripheral blood before and after RSPO3 induction and LGK974 treatment; n = 3 to 9 per group. (E) Representative images of hematoxylin and eosin–stained sternum sections showing a reversal of the RSPO3-induced bone marrow phenotype after LGK974 treatment; n = 3 to 10 per group. (F) Representative FACS plots and corresponding bar graph quantifying early B-progenitors in bone marrow from control and RSPO3 animals of each treatment group; n = 3 to 10 per group. Data shown are mean ± standard error of the mean and are representative of 2 independent experiments. One-way analysis of variance followed by Dunnett’s test for multiple comparisons. Scale bar, 500 μm. FITC, fluorescein isothiocyanate; IgM, immunoglobulin M; n.s., not significant (P > .05); PE, phycoerythrin; p.o., by mouth.